Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Early Mechanistic Events Induced by Secondhand Smoke Prevalent Low Molecular Weight Polycyclic Aromatic Hydrocarbons in Mouse Lung Epithelial Cells (Study ST001124)

Reversed phase NEGATIVE ION MODE (Analysis AN001849)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13	F14	F15	F16	F17	F18	F19	F20
15R-PGF2a	ME269452	0.99	0.27	0.58	1.10	1.42	3.87	0.68	1.21	1.82	4.81	0.52	0.33	0.64	0.26	0.33	0.30	0.16	0.18	0.18	0.25
PGE2	ME269451	1.44	0.21	0.43	1.11	1.69	4.44	0.49	0.81	1.78	5.76	0.19	0.18	0.38	0.17	0.19	0.16	0.12	0.09	0.12	0.17
5S-HETE	ME269482	1.06	0.80	NA	0.46	1.91	0.22	0.55	0.52	1.19	0.88	NA	1.77	0.65	1.26	NA	1.10	NA	NA	4.21	0.13
8-iso-PGF2a	ME269450	0.90	0.79	0.78	1.06	1.04	1.68	1.02	1.22	1.67	2.29	0.64	0.75	1.10	0.64	0.63	0.79	0.59	0.82	0.66	0.58
PGF2a	ME269453	0.98	0.66	0.79	1.03	1.18	2.27	0.84	1.08	1.35	2.69	0.83	0.68	0.83	0.65	0.68	0.67	0.63	0.62	0.63	0.65
Prostaglandin D2	ME269455	1.00	0.75	0.80	0.97	1.16	2.38	0.85	1.05	1.18	2.14	0.73	0.81	0.95	0.76	0.73	0.75	0.72	0.75	0.73	0.76
14(15)-EET	ME269477	0.73	1.28	0.82	1.77	0.86	0.60	0.93	0.92	1.77	1.45	1.24	0.59	0.74	0.79	0.92	1.17	0.30	1.01	1.07	1.09
15S-HETE	ME269475	0.74	1.09	0.84	1.41	1.05	0.92	1.21	0.95	1.74	1.41	1.05	0.87	0.57	0.80	0.89	1.19	0.39	0.91	0.93	1.04
15R-Lipoxin A4 (15R-LXA4)	ME269462	1.09	0.90	0.76	0.94	1.05	0.98	0.98	0.94	1.26	1.09	0.87	1.64	0.94	0.92	0.91	0.79	0.88	1.09	1.09	0.82
Lipoxin A4 (LXA4)	ME269461	1.04	0.83	0.98	1.07	1.04	1.02	0.89	0.83	1.16	1.33	1.07	1.29	1.10	0.78	0.93	0.84	0.83	0.89	1.12	0.94
8-iso-15R-PGF2a	ME269449	0.75	1.02	1.14	0.93	0.85	0.80	0.99	1.14	1.32	1.01	0.99	1.28	1.05	0.94	0.92	0.86	0.81	1.12	1.18	1.01
Resolvin D1 (RVD1)	ME269459	1.16	1.10	0.90	0.95	0.92	0.84	0.94	1.20	1.08	1.05	0.99	0.94	0.99	0.91	0.88	1.38	0.79	0.93	0.98	1.16
9-OxoODE	ME269478	1.10	1.00	1.13	1.02	0.86	0.80	0.89	1.11	0.91	0.87	1.14	0.87	1.00	1.13	1.11	0.90	0.84	1.18	1.09	1.07
8S-HETE	ME269481	0.97	1.14	1.02	1.17	1.08	0.91	1.01	0.98	1.10	1.16	0.89	1.08	0.92	0.99	0.82	0.98	0.78	1.02	1.08	0.91
12-HEPE	ME269470	0.99	0.99	0.98	1.01	1.02	0.98	1.00	0.96	0.98	1.02	1.08	1.22	0.94	0.98	0.97	0.96	0.92	1.01	1.01	0.98
17(S)-HDHA	ME269476	1.03	1.08	0.97	1.00	1.02	1.03	1.02	0.97	1.00	0.97	1.00	1.05	0.94	1.01	0.96	1.02	0.92	0.93	1.08	0.97
12S-HETE	ME269480	0.98	1.04	0.99	1.07	0.97	0.95	0.98	0.99	0.99	1.00	0.98	0.97	1.07	0.99	0.96	1.05	1.00	1.00	1.03	1.01
14(S)-HDHA	ME269479	1.00	1.03	0.97	1.05	1.01	1.02	0.97	0.99	0.98	1.01	0.99	1.01	1.00	1.00	0.99	1.02	0.93	1.00	0.99	0.98
8(9)-EET	ME269485	0.88	1.12	1.03	1.30	1.11	0.75	0.83	1.05	0.98	0.97	0.75	0.70	1.95	0.98	0.88	1.16	1.29	0.99	0.96	0.92
11(12)-EET	ME269483	0.90	1.03	0.88	1.21	0.83	0.79	0.86	0.99	0.91	0.94	1.08	0.78	1.47	0.96	0.92	1.21	1.36	0.83	0.97	1.16
Carbocyclic Thromboxane A2 (TXA2 analog)	ME269484	1.24	0.89	0.98	1.12	0.90	0.97	0.82	1.22	0.89	1.25	0.95	0.71	1.53	0.90	0.81	1.15	1.00	0.75	0.96	1.04

Factors:

F1	Treatment:2PAHS+p38inhibitor \| Time:12
F2	Treatment:2PAHS+p38inhibitor \| Time:2
F3	Treatment:2PAHS+p38inhibitor \| Time:24
F4	Treatment:2PAHS+p38inhibitor \| Time:4
F5	Treatment:2PAHS+p38inhibitor \| Time:8
F6	Treatment:2PAHs \| Time:12
F7	Treatment:2PAHs \| Time:2
F8	Treatment:2PAHs \| Time:24
F9	Treatment:2PAHs \| Time:4
F10	Treatment:2PAHs \| Time:8
F11	Treatment:DMSO \| Time:12
F12	Treatment:DMSO \| Time:2
F13	Treatment:DMSO \| Time:24
F14	Treatment:DMSO \| Time:4
F15	Treatment:DMSO \| Time:8
F16	Treatment:p38 inhibitor \| Time:12
F17	Treatment:p38 inhibitor \| Time:2
F18	Treatment:p38 inhibitor \| Time:24
F19	Treatment:p38 inhibitor \| Time:4
F20	Treatment:p38 inhibitor \| Time:8

Data matrix